A few thoughts about the state of our sector as of today. Biotech rebuilt its momentum after “Liberation Day” on April 7. Global indices have gained 60%+ and now sit 20% above January.
XBI index is back to January numbers. The rally looks convincing, but policy and execution risks remain.
Headwinds to track
- MFN price rules – Trial balloons from Washington hint at rebates for firms that match overseas prices. If adopted, headline revenue pressure will follow.
- Tariff threats – A proposed 200% levy on imported drugs moved markets less than the tweets that announced it, showcasing investors treat it as noise.
- Higher funding costs – The recent reconciliation package adds roughly USD 3 trillion to the deficit. More Treasury supply usually pushes yields up, lowering the present value of long-dated R&D programs.
- FDA bandwidth – Multiple sponsors report slippage in review timelines. It underscores capacity constraints inside the agency.
Tailwinds that fuel the rebound
- Volatility collapse – The VIX dropped from 42 in early April to the mid-teens, reducing the hurdle for risk capital.
- M&A momentum – Three deals above USD 10 bn have already cleared this year, recycling capital and validating pipelines.
- Fiscal stimulus – The OBBBA boosts aggregate demand and removes the orphan-drug penalty, widening commercial runways for rare-disease players.
- Supportive rhetoric – FDA and HHS leadership now speak openly about accelerating bioscience, offsetting last year’s anti-science narratives.
- Stable NIH funding outlook – Bipartisan voices in the Senate push back on deep research cuts, demonstrating continued public investment.
Bottom line
Challenges linger, but each looks fixable. Investors look to place money behind cash-rich companies with near-term data readouts.
With friendlier policies and steadier rates, the stage may be set for biotech to push forward.
* * *
I’m Dr. Julien Willard. I have experience as a health economist, strategy consultant, and a former intelligence professional. I help biopharma executives with business strategy, organizational transformation, and decision-making. I always write my own posts.